Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection

Annals of Gastroenterology

Volumn 22, Issue 4, 2009, Pages 263-267

  Karatapanis, Stylianos ^a   Skorda, L ^b   Georgopoulos, S ^c   Papantoniou, N ^a   Papastergiou, V ^a   Ntoutsikos, K ^a   Komnianides, ^a   Lisgos, Ph ^a  

^a General Hospital of Rhodes   (Greece)

^b General Hospital of Chalkida   (Greece)

^c Iatrikon Centre P Phaliron

Author keywords

First line therapy; H.pylori eradication therapy; Helicobacter pylori (H. pylori); Levofloxacin based therapies; Quadruple therapy; Second line therapy

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FECES COLOR; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; SIDE EFFECT; TASTE DISORDER; TREATMENT FAILURE; UREA BREATH TEST; VOMITING;

EID: 75749094746     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad hoc Committee on Practise Parameters of the American College of Gastroenetrology. Am J Gastroenterol 1998; 93:2330-2338
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-The Maasticht 2-2000 Consensus Report. Aliment Phrmacol Ther 2002; 16:167-180
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht III Consensus Report. Gut 2007; 56:772-781
4. Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999;13:289-95
5. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GUMACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999;13:703-712
6. Sheu BS, Wu JJ, Yang HB, et al. Lactobacillus and bifidobacteria containing yogurt can improve the drug compliance of triple therapy for Helicobacter eradication. Aliment Pharmacol Ther 2002; 16:1669-1675
7. Huang AH, Sheu BS, Yang HB, et al. Antimicrobial resistance of H. pylori to the outcome of one-week lansoprazole based triple therapy. J Formosan Med Assoc 2000; 90:704-709
8. Georgopoulos SD, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second line, Helicobacter pylori eradication therapies. Aliment Pharamcol Ther 2002; 16:569-575
9. Chi CH, Lin CY, Sheu BS, et al. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance to Helicobacter pylori. Aliment Pharmacol Ther 2003; 18:347-353
10. Kao AW, Cheng HC, Sheu BS, et al. Post-treatment C-urea breath test is predictive of antimicrobial resistance to H.pylori after failed therapy. Gen Intern Med 2005; 20:139-142
11. Parente F, Cucino C, Bianchi Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003; 35:523-528
12. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "Rescue" regimen when proton pump inhibitor-based triple therapies fail. Alim Pharmacol Ther 2002; 16:1047-1057
13. Gisbert JP, Pajares JM. Helicobacter "rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10:363-372
14. Croom KF, Goa KL. Levofloxacin : a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63:2769-2802
15. Saad RJ, Scoenfeld P, Kim HM, Chey WD. Levofloxacinbased triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a metanalysis. Am J Gastoenterol 2006;101:488-496
16. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23:488-496
17. Vaira D, Ricci C, Lanzini A, et al. How to proceed in Helicobacter pylori-positive chronic gastritis refractory to first and second-line eradication therapy. Dig Dis 2007; 25:203-205
18. Sanchez JE, Saenz NG, Rincon MR, et al. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/ dalfopristin and new quinolones. J Antimicob Chemother 2000; 46:283-285
19. Xia HH, Yu Wong BC, Talley NJ, Lam SK. Alternative and rescue treatment regimens for Helicobacter pylori eradication Expert Opin Pharmacother 2002; 2:1301-1311
20. Antos D, Scneider-Brachert W, Bastlein E, et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006; 11:39-45
21. Kumula W, Rani A. Patterns of Helicaobacter pylori isolate resistance to fluoroquinolones, amoxicillin, clarithromycin and metronidazoles. Souteast Asian J Trop Med Public Health 2006; 37:970-974
22. Tanaka N, Isogai E, Isogai H, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002; 49:1039-1040
23. Rispo A, Di Girolamo E, Cozzolino A, et al. Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter 2007; 12:364-365
24. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, et al. First line triple therapy with levofloxacin for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26:495-500
25. Lee JH, Hong SP, Kwon CL, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006; 48:19-24
26. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35:711-715
27. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection : a controlled trial. Clin Gastroenterol Hepatol 2004; 2:997-1002
28. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who failed two eradication courses. Aliment Phrmacol Ther 2005; 22:45-49
29. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin versus metronidazole-based rescue therapy for h.pylori infection in Japan. Dig Liver Dis 2005; 37:821-825
30. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs quadruple therapy in second line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003; 18:627-633
31. Orsi P, Pinazzi O, Aragona G, Di Mario F. Rabeprazole/Levofloxacin based triple therapy as a Salvatage Treatment after failure of H.pylori eradication with standard regimens. Helicobacter 2003; 8:339-493
32. Perri F, Festa V, Merla A, et al. Randomized study of different "second-line" therapies for Helicobacter pylori infection after failure of the standard "Maastricht triple therapy" Aliment Pharmacol Ther 2003; 18:815-820
33. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23:421-427
34. Gisbert JP, Bermejo F, Castro-Fernandez M, et al. Second line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008;1 03:71-76
35. Giannini EG, Bilardi C, Dulbecco P, et al. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006; 23:281-287
36. Page RL, Ferguson D, Cantu M. An alternative salvage regimen for Helicobacter pylori-resistant patients with heart failure. Cardiology 2008; 110:112-115
37. Lee YC, Wu HM, Chen TH, et al. A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures. Helicobacter 2006; 11:418-424
38. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 Suppl. 3:32-37, discussion 4-48
39. Carothers JJ, Bruce MG, Hennesy TW, et al. The relationship between previous fluoroquinolones use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007; 44:e5-e8
40. Cattoir V, Nectoux J, Lascols C, et al. Update on fluoroquinolone resistance in Helicobacter pylor: new mutations leading to resistance and first prescription of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007; 29:389-396
41. Perna F, Zullo A, Ricci C, et al. Levofloxacin-based triple therapy for Helicobacter pylori retreatment: role of bacterial resistance. Dig Liver Dis 2007; 39:1001-1005